Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.

G. Dark, S A Hill, Vivien E. Prise, +3

PubMed

Vascular ShutdownTumor BiologyOncologyCancer Cell BiologySelective Toxicity +14

Differentiation and Definition of Vascular-Targeted Therapies

Dietmar W. Siemann, Michael C. Bibby, G. Dark, +5

Clinical Cancer Research

Proven bioequivalence of blood exposure between vinorelbine 80 mg/m² oral and 30 mg/m² IV doses in cancer patients

Hugues Bourgeois, Jan B. Vermorken, G. Dark, +7

Journal of Clinical Oncology

Blood ExposurePharmacotherapyCancer PatientsOral ChemotherapyPharmacodynamic Modeling +19

Surveillance policy for stage I ovarian germ cell tumors.

G. Dark, Mark Bower, E.S. Newlands, +2

Journal of Clinical Oncology

Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial

Giorgio V. Scagliotti, C. Kortsik, G. Dark, +12

Clinical Cancer Research

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

Martin Gore, Allan Hackshaw, William E. Brady, +19

Gynecologic Oncology

Meoc/gog 0241Gynecological SurgeryMedicineCancer ManagementPhase Iii +7

Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program

Paul Taylor, B. Castagneto, G. Dark, +12

Journal of Thoracic Oncology

Surgical OncologyOncologyMalignant Pleural MesotheliomaPleural DiseaseSingle-agent Pemetrexed +2

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)

Richard Booton, Paul Lorigan, Heather Anderson, +10

Annals of Oncology

Mitomycin C/vinblastine/cisplatinMedicineMetronomic TherapyPhase Iii TrialClinical Trials +8

Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group

G. Dark, A H Calvert, Robert Grimshaw, +15

Journal of Clinical Oncology

Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

Robert D. Morgan, Iain A. McNeish, Adrian Cook, +22

The Lancet Oncology

Gastrointestinal OncologyMedicinePost-hoc Exploratory AnalysisGynecologyFallopian Tube +6